EYETECH PHARMACEUTICALS INC 4
4 · EYETECH PHARMACEUTICALS INC · Filed Dec 21, 2004
Insider Transaction Report
Form 4
ALTSCHULER DOUGLAS H
Sr VP, Legal, General Counsel
Transactions
- Sale
Common Stock
2004-12-20$43.58/sh−8,000$348,640→ 333 total - Exercise/Conversion
Common Stock
2004-12-20$3.50/sh+2,976$10,416→ 3,309 total - Sale
Common Stock
2004-12-20$43.58/sh−2,976$129,694→ 333 total - Sale
Common Stock
2004-12-20$43.58/sh−21,024$916,226→ 333 total - Exercise/Conversion
Common Stock
2004-12-20$3.50/sh+21,024$73,584→ 21,357 total - Exercise/Conversion
Incentive Stock Option (right to buy)
2004-12-20−2,976→ 17,262 totalExercise: $3.50From: 2004-07-07Exp: 2013-07-07→ Common Stock (2,976 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2004-12-20−21,024→ 105,405 totalExercise: $3.50From: 2004-07-07Exp: 2013-07-07→ Common Stock (21,024 underlying) - Award
Non-Qualified Stock Option (right to buy)
2004-12-09+25,000→ 25,000 totalExercise: $43.55From: 2005-12-09Exp: 2014-12-08→ Common Stock (25,000 underlying)
Footnotes (1)
- [F1]The option becomes exercisable with respect to the first 25% of the original number of shares on the first aniversary of the grant date (as specified in column 3) and an additional 2.08333% of the original number of shares at the end of each successive monthly period following the first anniversary of the grant date.